A Reactive Oxygen Species Scoring System Predicts Cisplatin Sensitivity and Prognosis in Ovarian Cancer Patients

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Nov 10

PMID 31703584

Citations 13

Authors

Chaoyang Sun

Ensong Guo

Bo Zhou

Wanying Shan

Jia Huang

Danhui Weng

Peng Wu

Changyu Wang

Shixuan Wang

Wei Zhang

Qinglei Gao

Xiaoyan Xu

Beibei Wang

Junbo Hu

Ding Ma

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Background: To reveal roles of reactive oxygen species (ROS) status in chemotherapy resistance and to develop a ROS scoring system for prognosis prediction in ovarian cancer.

Methods: We tested the sensitizing effects of ROS elevating drugs to cisplatin (cDDP) in ovarian cancer both in vitro and in vivo. A ROS scoring system was developed using The Cancer Genome Atlas (TCGA) database of ovarian cancer. The associations between ROS scores and overall survival (OS) were analyzed in TCGA, Tothill dataset, and our in-house dataset (TJ dataset).

Results: ROS-inducing drugs increased cisplatin-induced ovarian cancer cell injury in vitro and in vivo. ROS scoring system was established using 25 ROS-related genes. Patients were divided into low (scores 0-12) and high (scores 13-25) score groups. Improved patient survival was associated with higher scores (TCGA dataset hazard ratio (HR) = 0.43, P < 0.001; Tothill dataset HR = 0.65, P = 0.022; TJ dataset HR = 0.40, P = 0.003). The score was also significantly associated with OS in multiple datasets (TCGA dataset r = 0.574, P = 0.032; Thothill dataset r = 0.266, P = 0.049; TJ dataset r = 0.632, P = 0.001) and with cisplatin sensitivity in ovarian cancer cell lines (r = 0.799, P = 0.016) when used as a continuous variable. The scoring system showed better prognostic performance than other clinical factors by receiver operating characteristic (ROC) curves (TCGA dataset area under the curve (AUC) = 0.71 v.s. 0.65, Tothill dataset AUC = 0.73 v.s. 0.67, TJ dataset AUC = 0.74 v.s. 0.66).

Conclusions: ROS status is associated with chemotherapy resistance. ROS score system might be a prognostic biomarker in predicting the survival benefit from ovarian cancer patients.

Citing Articles

Activity of NAD(P)H-Oxidoreductases in Ovarian Cancer.

Fedorova M, Voznesensky V, Sosnova E, Proskurnina E Biomedicines. 2024; 12(5).

PMID: 38791014 PMC: 11117946. DOI: 10.3390/biomedicines12051052.

Sol-gel synthesis and cytotoxicity evaluation of selenium-doped cerium oxide nanoparticles for biomedical applications.

Javid H, Amiri H, Hashemi S, Reihani A, Esparham A, Hashemy S Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):3437-3447.

PMID: 37962586 DOI: 10.1007/s00210-023-02823-9.

Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells.

Abdalbari F, Martinez-Jaramillo E, Forgie B, Tran E, Zorychta E, Goyeneche A Cancers (Basel). 2023; 15(21).

PMID: 37958311 PMC: 10650616. DOI: 10.3390/cancers15215136.

NFIXing Cancer: The Role of NFIX in Oxidative Stress Response and Cell Fate.

Ribeiro V, Martins S, Lopes A, Thorsteinsdottir S, Zilhao R, Carlos A Int J Mol Sci. 2023; 24(5).

PMID: 36901722 PMC: 10001739. DOI: 10.3390/ijms24054293.

The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2-A Systematic Review.

Krejbich P, Birringer M Antioxidants (Basel). 2022; 11(11).

PMID: 36358521 PMC: 9686580. DOI: 10.3390/antiox11112149.

References

Kumari S, Badana A, G M, G S, Malla R . Reactive Oxygen Species: A Key Constituent in Cancer Survival. Biomark Insights. 2018; 13:1177271918755391. PMC: 5808965. DOI: 10.1177/1177271918755391. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Boonstra J, Post J . Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene. 2004; 337:1-13. DOI: 10.1016/j.gene.2004.04.032. View

Conklin K . Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004; 3(4):294-300. DOI: 10.1177/1534735404270335. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Zhang W, Hu X, Shen Q, Xing D . Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy. Nat Commun. 2019; 10(1):1704. PMC: 6461692. DOI: 10.1038/s41467-019-09566-3. View

Liu J, Wang Z . Increased Oxidative Stress as a Selective Anticancer Therapy. Oxid Med Cell Longev. 2015; 2015:294303. PMC: 4529973. DOI: 10.1155/2015/294303. View

Ilyasova D, Kennedy K, Spasojevic I, Wang F, Tolun A, Base K . Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat. 2010; 125(2):583-9. PMC: 3500598. DOI: 10.1007/s10549-010-1158-7. View

Liou G, Storz P . Reactive oxygen species in cancer. Free Radic Res. 2010; 44(5):479-96. PMC: 3880197. DOI: 10.3109/10715761003667554. View

10.

Sun C, Su T, Li N, Zhou B, Guo E, Yang Z . A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma. Oncotarget. 2015; 7(3):3245-54. PMC: 4823103. DOI: 10.18632/oncotarget.6569. View

11.

Wang J, Yi J . Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008; 7(12):1875-84. DOI: 10.4161/cbt.7.12.7067. View

12.

Postovit L, Widmann C, Huang P, Gibson S . Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy. Oxid Med Cell Longev. 2018; 2018:6135739. PMC: 5994291. DOI: 10.1155/2018/6135739. View

13.

Kmet L, Cook L, Magliocco A . A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. 2003; 97(2):389-404. DOI: 10.1002/cncr.11064. View

14.

Prahm K, Hogdall C, Karlsen M, Christensen I, Novotny G, Hogdall E . Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS One. 2018; 13(11):e0207319. PMC: 6261038. DOI: 10.1371/journal.pone.0207319. View

15.

Filippova M, Filippov V, Williams V, Zhang K, Kokoza A, Bashkirova S . Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. Biomed Res Int. 2014; 2014:574659. PMC: 4248402. DOI: 10.1155/2014/574659. View

16.

Zhang J, Lei W, Chen X, Wang S, Qian W . Oxidative stress response induced by chemotherapy in leukemia treatment. Mol Clin Oncol. 2018; 8(3):391-399. PMC: 5867396. DOI: 10.3892/mco.2018.1549. View

17.

Li H, Gao Q, Guo L, Lu S . The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther. 2011; 11(11):950-8. DOI: 10.4161/cbt.11.11.15531. View

18.

Molavian H, Goldman A, Phipps C, Kohandel M, Wouters B, Sengupta S . Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects. Sci Rep. 2016; 6:27439. PMC: 4899687. DOI: 10.1038/srep27439. View

19.

Stiewe T, Haran T . How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resist Updat. 2018; 38:27-43. DOI: 10.1016/j.drup.2018.05.001. View

20.

Chiang A, Chen J, Chung Y, Huang H, Liou W, Chang C . A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer. J Gynecol Oncol. 2014; 25(1):51-7. PMC: 3893675. DOI: 10.3802/jgo.2014.25.1.51. View